VEZT Antibody

What is VEZT protein and what is its cellular localization pattern?

VEZT (vezatin) is a transmembrane protein primarily localized in cell membranes, particularly at adherens junctions. It is also found in the nucleus and acrosome . Functionally, VEZT plays crucial roles in cell-cell adhesion and may be involved in various cellular signaling pathways. The protein has a theoretical molecular weight of approximately 83 kDa, though observed molecular weight may vary due to post-translational modifications, cleavages, and experimental factors .

The protein's subcellular distribution pattern includes:

For accurate localization studies, immunocytochemistry with proper controls is recommended to confirm subcellular distribution patterns in your specific cell type of interest.

What are the validated applications for commercially available VEZT antibodies?

Commercial VEZT antibodies have been validated for multiple experimental applications. The Novus Biologicals VEZT polyclonal antibody has been specifically validated for :

When selecting an application, consider that the epitope accessibility may vary between techniques due to differences in sample preparation. For example, in Western blot, the protein is denatured, exposing linear epitopes, while in immunohistochemistry, the epitope conformation depends on fixation and antigen retrieval methods .

How can I properly validate VEZT antibody specificity for my experimental system?

For rigorous validation of VEZT antibody specificity, follow the five pillars approach recommended by the International Working Group for Antibody Validation (IWGAV) :

• Genetic strategies: Use CRISPR-Cas9 or RNAi to knockdown VEZT expression and confirm reduced or absent signal.

• Orthogonal strategies: Compare antibody results with an antibody-independent method (e.g., mass spectrometry or RNA expression).

• Independent antibody verification: Use at least two antibodies raised against different epitopes of VEZT and compare staining patterns.

• Expression of tagged proteins: Express tagged VEZT protein and confirm co-localization with antibody staining.

• Immunocapture followed by mass spectrometry: Perform immunoprecipitation with the VEZT antibody followed by mass spectrometry to confirm target identity.

A robust validation should employ at least two of these methods. For VEZT specifically, the specificity of some commercially available antibodies has been verified using protein arrays containing the target protein plus 383 other non-specific proteins , providing an additional layer of confidence.

What controls should I include when using VEZT antibody in immunohistochemistry experiments?

For rigorous immunohistochemistry experiments with VEZT antibody, include the following controls:

• Positive tissue control: Use tissue known to express VEZT (e.g., colon carcinoma tissues have shown positive staining) .

• Negative tissue control: Use tissue known to have low or no VEZT expression.

• Antibody controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at the same concentration)

  • Blocking peptide control (pre-incubate antibody with immunizing peptide)

• Technical controls:

  • Include both positive and negative controls in each experiment

  • Process all slides simultaneously under identical conditions

  • Use standardized antigen retrieval methods

• Validation by orthogonal method: Compare IHC results with RNA expression data or protein levels determined by Western blot .

For paraffin-embedded tissues, optimize antigen retrieval conditions, as they significantly impact epitope exposure and antibody binding. For VEZT antibody, dilutions between 1:100-1:1000 have been reported as effective for paraffin sections .

How do I optimize Western blot protocols for VEZT antibody to minimize non-specific binding?

To optimize Western blot protocols for VEZT antibody and reduce non-specific binding:

• Sample preparation:

  • Use fresh tissue/cell lysates with protease inhibitors

  • Ensure complete protein denaturation (VEZT is a membrane protein)

  • Load appropriate protein amount (20-50 μg for cell lysates)

• Blocking optimization:

  • Test different blocking agents (5% non-fat milk, 5% BSA, commercial blockers)

  • Extend blocking time to 2 hours at room temperature or overnight at 4°C

• Antibody optimization:

  • Perform antibody titration (test range: 1:500-1:3000)

  • Incubate primary antibody overnight at 4°C in blocking buffer

  • Include 0.1% Tween-20 in antibody diluent to reduce background

• Washing steps:

  • Increase number and duration of washes (5-6 washes, 10 minutes each)

  • Use TBS-T (0.1% Tween-20) for washing

• Detection system:

  • Use highly sensitive ECL systems for weak signals

  • Consider fluorescent secondary antibodies for quantitative analysis

• Controls:

  • Include positive control (tissue with known VEZT expression)

  • Include negative control (tissue with low VEZT expression or VEZT knockdown)

Western blot data shows that VEZT antibody NBP2-20855 detects a band at the expected molecular weight in various tissue extracts, with strong signals in heart, spleen, and testis tissues .

What are the methodological considerations for using VEZT antibody in studies involving protein complexes?

When studying VEZT in protein complexes, consider these methodological approaches:

• Sample preparation for maintaining complex integrity:

  • Use mild, non-denaturing lysis buffers

  • Include reversible crosslinking agents (e.g., DSP, formaldehyde)

  • Maintain physiological salt concentrations

  • Include phosphatase inhibitors to preserve phosphorylation-dependent interactions

• Co-immunoprecipitation optimization:

  • Pre-clear lysates to reduce non-specific binding

  • Use recombinant protein G or A/G beads for clean pull-downs

  • Consider magnetic beads for gentle elution

  • Optimize antibody concentration (typically 2-5 μg per mg of protein lysate)

• Complex-specific approaches:

  • Consider the fusion protein approach described for other protein complexes

  • Create a fusion construct of VEZT with its binding partner

  • Use the fusion protein as an immunogen to generate complex-specific antibodies

• Verification methods:

  • Reciprocal co-IP with antibodies against interaction partners

  • Mass spectrometry analysis of immunoprecipitated complexes

  • Proximity ligation assay to visualize protein-protein interactions in situ

  • FRET or BiFC to detect direct interactions in living cells

Recent research has demonstrated that fusion protein approaches can overcome limitations in generating antibodies against protein complexes. For example, researchers at Vanderbilt University Medical Center and Sanford Burnham Prebys successfully generated complex-specific antibodies by fusing interacting proteins (BTLA and HVEM) . This approach could potentially be adapted for VEZT and its binding partners.

How can computational approaches enhance VEZT antibody design and epitope prediction?

Computational approaches can significantly enhance VEZT antibody design and epitope prediction through several methods:

• Antibody structure modeling:

  • Homology modeling using known antibody structures as templates

  • Ab initio modeling for CDR loops, especially H3 loops

  • Optimization of VH/VL interface

  • Programs like RosettaAntibody can generate preliminary models by selecting different templates for frameworks and CDRs

• Epitope prediction and optimization:

  • In silico prediction of VEZT epitopes based on:

    • Surface accessibility

    • Hydrophilicity profiles

    • Secondary structure propensity

    • B-cell epitope prediction algorithms

  • AI-based approaches for epitope-paratope interaction prediction

• Antibody affinity enhancement:

  • Machine learning models like AbRFC to predict affinity-enhancing mutations

  • Molecular dynamics simulations to identify key residues for binding

  • Computational alanine scanning to identify hotspot residues

• Stability optimization:

  • Prediction of aggregate-prone regions (APRs)

  • Design of mutations to improve stability while maintaining specificity

  • Simulation of different buffer conditions to optimize formulation

Recent advancements at Vanderbilt University Medical Center involve using AI technologies to generate antibody therapies against specific antigen targets. Their project, funded with up to $30 million from ARPA-H, aims to build a massive antibody-antigen atlas and develop AI-based algorithms to engineer antigen-specific antibodies . Similarly, researchers have demonstrated atomically accurate de novo design of single-domain antibodies using computational methods combined with experimental screening .

What are common issues when using VEZT antibody and their solutions?

When troubleshooting, systematically modify one variable at a time and document all changes to identify the source of the problem. For VEZT antibody specifically, ensure you're using the recommended concentration for each application as specified in the product documentation .

How can I quantitatively assess VEZT expression levels across different samples?

For quantitative assessment of VEZT expression across different samples:

• Western blot quantification:

  • Use fluorescent secondary antibodies rather than chemiluminescence

  • Include a loading control (β-actin, GAPDH, or total protein stain)

  • Generate standard curves using recombinant VEZT protein

  • Use image analysis software (ImageJ, Image Lab) for densitometry

  • Calculate relative expression: (VEZT signal/loading control signal)

• Flow cytometry quantification:

  • Use cellular permeabilization for intracellular VEZT detection

  • Include calibration beads with known antibody binding capacity

  • Calculate molecules of equivalent soluble fluorochrome (MESF)

  • Use median fluorescence intensity (MFI) for comparison

• Quantitative immunohistochemistry:

  • Use automated staining platforms for consistency

  • Include reference standards on each slide

  • Employ digital image analysis systems with color deconvolution

  • Quantify by H-score, Allred score, or percentage positive cells

• Advanced quantification approaches:

  • Multiplex immunofluorescence for co-expression analysis

  • Mass cytometry (CyTOF) for single-cell protein quantification

  • Proximity ligation assay for quantifying protein-protein interactions

  • ELISA or Luminex assays for VEZT in solution

• Statistical analysis:

  • Use appropriate statistical tests based on data distribution

  • Consider finite mixture models for antibody data analysis

  • Employ scale mixtures of Skew-Normal distributions for improved statistical modeling of antibody data

When analyzing antibody data for quantification, finite mixture models can provide robust statistical frameworks. Research by Domingues et al. demonstrated that scale mixtures of Skew-Normal distributions can effectively model antibody data, particularly for distinguishing between positive and negative populations .

How can I design experiments to study VEZT's role in specific cellular processes?

To design experiments investigating VEZT's role in cellular processes:

• Functional knockdown/knockout studies:

  • Use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate VEZT expression

  • Create stable cell lines with inducible VEZT knockdown

  • Use rescue experiments with wild-type or mutant VEZT to confirm specificity

  • Analyze phenotypic changes in cell adhesion, morphology, and motility

• Structure-function relationship studies:

  • Generate truncation mutants to identify functional domains

  • Create point mutations in predicted functional sites

  • Use domain-specific antibodies to block particular functions

  • Perform co-immunoprecipitation with truncation mutants to map interaction domains

• Dynamic studies of VEZT localization:

  • Create fluorescent protein fusions (VEZT-GFP, VEZT-mCherry)

  • Perform live-cell imaging during cellular processes of interest

  • Use FRAP (Fluorescence Recovery After Photobleaching) to study protein dynamics

  • Apply optogenetic tools to manipulate VEZT function in specific subcellular regions

• Pathway analysis:

  • Use phospho-specific antibodies to monitor VEZT phosphorylation state

  • Apply specific pathway inhibitors to identify regulatory mechanisms

  • Perform global phosphoproteomics after VEZT manipulation

  • Use proximity labeling methods (BioID, APEX) to identify local interactome

• Physiological models:

  • Develop transgenic animal models with tissue-specific VEZT manipulation

  • Use organoid cultures to study VEZT in a 3D tissue-like context

  • Apply mechanical stress to study VEZT's role in mechanotransduction

  • Analyze VEZT in disease models relevant to cell adhesion defects

Recent advances in protein complex-specific antibody development, as demonstrated in the BTLA-HVEM system , could be adapted to study VEZT's interactions with binding partners. Additionally, emerging AI-based approaches for antibody design and epitope targeting might enable development of more specific tools for VEZT functional studies.

How might AI and computational methods revolutionize VEZT antibody development?

AI and computational methods are poised to transform VEZT antibody development through several innovative approaches:

• De novo antibody design:

  • Recent breakthrough research has demonstrated atomically accurate de novo design of single-domain antibodies using computational methods

  • Fine-tuned RFdiffusion networks combined with experimental screening can generate antibodies that bind specified epitopes with atomic-level precision

  • These approaches could be applied to designing VEZT-specific antibodies targeting precise epitopes of interest

• AI-driven antibody engineering:

  • Machine learning models like AbRFC can predict affinity-enhancing mutations that maintain epitope specificity

  • Vanderbilt University Medical Center's $30 million ARPA-H-funded project aims to build a massive antibody-antigen atlas and develop AI algorithms to engineer antigen-specific antibodies

  • These technologies could address traditional antibody discovery bottlenecks including inefficiency, high costs, and limited scalability

• Large-scale data mining approaches:

  • Analysis of billions of human antibody variable region sequences can identify highly public antibodies that appear across multiple individuals

  • Researchers found that 0.07% of unique CDR-H3s occur in at least five of 135 bioprojects, and 6% of therapeutic CDR-H3s match this small shared set

  • This suggests focusing on this subspace of public CDR-H3s could be valuable for therapeutic antibody design

• Integrated computational-experimental pipelines:

  • Combined approaches using computational prediction followed by high-throughput experimental validation

  • Design-Build-Test-Learn cycles can rapidly iterate and improve antibody properties

  • This could enable development of VEZT antibodies with superior specificity, affinity, and developability

As these technologies mature, they could enable rapid development of multiple VEZT antibodies with distinct epitope specificities and optimized properties for specific research applications.

What emerging applications of VEZT antibodies should researchers be aware of?

Researchers should monitor these emerging applications of VEZT antibodies:

• Liquid biopsy biomarkers:

  • VEZT detection in circulating tumor cells or extracellular vesicles

  • Development of sensitive ELISA or other immunoassays for VEZT in biofluids

  • Potential diagnostic applications in cancers where VEZT expression is altered

• Therapeutic targeting:

  • Development of function-blocking antibodies to modulate VEZT-dependent adhesion

  • Creation of antibody-drug conjugates targeting VEZT-expressing cells

  • CAR-T or other immunotherapy approaches if VEZT shows tumor-specific patterns

• Advanced imaging applications:

  • Super-resolution microscopy for nanoscale localization of VEZT

  • Multiplexed imaging to study VEZT in its protein interaction network

  • Intravital imaging using VEZT antibodies for studying dynamic processes in vivo

• Single-cell analysis:

  • Integration of VEZT antibodies into CyTOF or CODEX platforms

  • Correlation of VEZT protein levels with transcriptomics at single-cell resolution

  • Spatial proteomics to understand VEZT distribution within tissue architecture

• Complex-specific antibodies:

  • Development of antibodies specific to VEZT in complex with its binding partners

  • Application of fusion protein approaches similar to the BTLA-HVEM system

  • These tools could provide new insights into VEZT's functional interactions

• Targeted protein degradation:

  • VEZT antibodies as targeting moieties for PROTAC or other degrader technologies

  • Selective degradation of VEZT to study acute loss of function

  • Potential therapeutic applications in disease contexts

Researchers should continuously monitor the literature for new developments in these emerging applications as antibody technologies and their applications continue to evolve rapidly.